Se@Albumin nanoparticles ameliorate intestinal mucositis caused by cisplatin<i>via</i>gut microbiota-targeted regulation
Liping Deng, Hongliang Zeng, Xueying Hu, Mengqing Xiao, Dong He, Yao Zhang, Yi Jin, Yibo Hu, Yuxing Zhu, Lian Gong, Zhanwang Wang, Liang Xiang, Rongrong Zhu, Yeyu Zhang, Yaxin Cheng, Xingyu Chen, Shuihan Zhang, Yongbo Peng, Ke Cao
Abstract
Chemotherapy-associated intestinal mucositis is still one of the major challenges in the first-line clinical cancer treatment. Selenium element has shown health benefits on enteritis upon uptake in trace amounts; however, it was limited because of its narrow safety margin. In this work, a new form of Se@Albumin complex nanoparticles (Se@Albumin NPs) was developed by self-assembly of denatured human serum albumin and selenite salts. Se@Albumin NPs significantly improve intestinal mucositis induced with cisplatin (CDDP) in a mouse model via attenuating the level of intestinal oxidative stress, reducing intestinal permeability, and relieving gastric dysmotility. It is very interesting that the restoration of anti-inflammatory bacteria (Bacteroidetes and Firmicutes) and reduced abundance of proinflammatory bacteria (Escherichia) contributed to the reduction of intestinal mucositis by Se@Albumin NPs in mice. In addition, the fecal microbiota transplantation (FMT) with materials from Se@Albumin NP-treated mice significantly protected pseudo-aseptic mice from CDDP-induced intestinal mucositis. In conclusion, our findings showed that Se@Albumin NPs can significantly improve CDDP-induced intestinal mucositis, and its function may be directly mediated by gut microbiota regulation, which will provide new helpful information for clinical treatment.